Redcare Pharmacy N.v. · XETR:RDC
Redcare Pharmacy — Q1 2025 Earnings Presentation
22 slides from Redcare Pharmacy's earnings presentation, May 6, 2025
Slide 1: Earnings call presentation: Q1 2025
Earnings call presentation: Qi 2025. @SEVENUM, 6 MAY 2025__—i+d: ¥ Redcare
Slide 2: Presenting live from Sevenum
Slide 3: Today's presenters
Today’s presenters. Olaf Heinrich, Chief Executive Officer. Jasper Eenhorst, Chief Financial Officer. A]
Slide 4: Today's agenda
Today’s agenda. €&> Financial performance. ¥ C2) General update. © C3) Outlook and guidance 2025. (Qo 5
Slide 5: Financial performance
Financial performance.
Slide 6: Q1 2025 financial highlights
@ FINANCIAL PERFORMANCE Qi 2025 financial highlights. > Successful start with continued fast growth. Group sales up 28% year over year in Qi 2025, fully organic and driven by Rx, reaching EUR 717M. > Non-Rx growth 20%. +17% in the DACH segment and +26% in the International segment. > Fast year-over-
Slide 7: Key financials | Sales
@ KEY FINANCIALS | SALES Growth across all regions: total sales up 28%, strong Rx momentum in Germany continues. Total DACH International +28.0% v4 +28.5% P< EUR EUR cuR 717M cuR 135M 560M 453M Qi 2024 Qi 2025 Qi 2024 Qi 2025 Qi 2024 Qi 2025
Slide 8: Financial KPIs
INANCIAL KPIs Rx drives higher basket value and customer base. @ Number of customers in millions +0.6M Not just Net Promoter Score mae Polen Qi 2025 (at 2024: 70) +0.4M 13.1M +0.4M 414.2M +41.9M p € 62.44 Average shopping basket value Mar 2024 Mar 2025 Qi 2025 (a1 2024: 58.92) Definition: average gr
Slide 9: Non-financial KPIs
@ NON-FINANCIAL KPIs Orders rising to new highs, @ Number of orders in millions Share of repeat orders in percentage of total 81% 82% 83% 81% ai Q2 Q3 Q4 2021 81% ai 2022 83% Q2 85% Q3 84% Q4 84% ai 2023 84% Q2 86% Q3 up year over year 2.6M to 11.5M. 11.5 10.4 8.9 | 37 | 38 a4 a@t @2 @3 @ at 2024 Or
Slide 10: Key financials | Profit&Loss
@ KEY FINANCIALS | PROFIT&LOSS _) Sales up 28% year over year, with positive EBITDA. Quarter-over-quarter improvement on all levels. Quarter over quarter Year over year in millions of euro, adjusted numbers Q4 2024 Qi 2025 _ Better or (worse) Qi 2024 Qi 2025 Better or (worse) Sales 675 717 6.2% 560
Slide 11: Key financials | Gross profit margin
@ KEY FINANCIALS | GROSS PROFIT MARGIN ) Gross margin stable year over year and improved quarter over quarter. Adjusted gross profit margin Adjusted gross profit margin in percentage of sales in percentage of sales 30.3% 23.3% 23.4% 23.3% Q4 2024 Qi 2025 Qi 2024 Product Country mix, Rx Other 12025 m
Slide 12: Key financials | Selling, distribution and admin ratio
@ KEY FINANCIALS | SELLING, DISTRIBUTION AND ADMIN RATIO ) Higher marketing spend in part offset by productivity and scale. Adjusted SD&A costs Adjusted SD&A costs in percentage of sales in percentage of sales ¥ (23.0%) (22.4%) ied) (22.1%) 4 2024 Qi 2025 Qi 2024 $&D Admin Qi 2025 12 I]
Slide 13: Cash flow EUR +7M in Q1
Cash flow EUR +7M in Q1. Operating result Cash flow EUR +7 million. in millions of euro Working capital EUR +30 million. Mainly from seasonality. 7 30 (19) (10) lavestrnents EUR -19 million. 185 IT and PP&E, including the 178 commencement of e-Rx automation project. Financing 31 Dec 2024 31 Mar 2025
Slide 14: General update
ie? General update.
Slide 15: Redcare's Rx market share keeps growing
Redcare’s Rx market share keeps growing. Redcare’s market share of Rx sales in Germany per monthly average; numbers shown are for the last month of the quarter. 0.87% Assuming a EUR 55 billion addressable market. ai Q2 Q3 a4 ai 2024 2025 Source: calculated by Redcare using ABDA / Insight Health mark
Slide 16: Successful transformation into an app business
Successful transformation into an app business. Customers Share of Redcare Rx prescriptions by channel received". > One-stop pharmacy on smartphone: mgematik app QR code scan a pharmacy at your finger-tip. Shop Apotheke app / CardLink Mail (QR code and paper) sou pe > Fully digital journey. > Conven
Slide 17: Rx strategy
@ RX STRATEGY Rx cohorts already outperform strong non-Rx cohorts in year 1 by a multiple. Indexed accumulated sales per new customer (total cohort) Indexed accumulated gross profit per new customer (total cohort) 1100 1100 900 900 Rx QL 700 700 x47 500 x4.5 ees x38 PERE 300 300 Non-Rx Qt | x24 Non-
Slide 18: Convertible bonds
@ CONVERTIBLE BONDS Successful placement of new convertible bonds and buy-back of existing on 8 April. Rationale: >» Refinance outstanding 2021 convertible bond, lengthening the maturity profile. Previous 7-year bond included a put option right for investors for repayment in January 2026. >» Pro-act
Slide 19: Outlook and guidance 2025
Outlook and guidance 2025. A]
Slide 20: Guidance, full-year 2025
(@ OUTLOOK AND GUIDANCE 2025 Guidance, full-year 2025. > Total sales growth in excess of 25%. > Rx in Germany in excess of EUR 0.5 billion. > Non-Rx total company growth in excess of 18%. > Adj. EBITDA margin positive 2% to 2.5%. The market and industry remain dynamic. As always, we will optimise gr
Slide 21: Redcare questions
¥ Redcare questions. ask
Slide 22: Interim Report Q1 2025 available online
@sEVENUMI6 MAY 2025 _) Interim Report Qi 2025 can be downloaded on our website: www.ir.redcare-pharmacy.com ¥ Redcare